AAO: 2018
Pravin U. Dugel, MD
Show Description +
Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the 48-week data, focusing in particular on anatomic results.
Posted: 10/09/2018
Pravin U. Dugel, MD
Pravin U. Dugel, MD, details the results of the phase 3 HAWK and HARRIER studies evaluating brolucizumab (Novartis) for the treatment of wet age-related macular degeneration. Dr. Dugel compares data from the 96-week endpoint to the 48-week data, focusing in particular on anatomic results.
Posted: 10/09/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2018.
Please log in to leave a comment.